Calcium Homeostasis Modulation Therapy for Neurodegeneration

Overview

This therapeutic approach targets dysregulated calcium signaling in neurodegenerative diseases by modulating mitochondrial calcium uniporter (MCU) complexes, store-operated calcium entry (SOCE) channels, and plasma membrane calcium ATPase (PMCA) activity to restore neuronal calcium homeostasis and prevent excitotoxic cell death.

10-Dimension Rubric Scoring

Overview

This therapeutic approach targets dysregulated calcium signaling in neurodegenerative diseases by modulating mitochondrial calcium uniporter (MCU) complexes, store-operated calcium entry (SOCE) channels, and plasma membrane calcium ATPase (PMCA) activity to restore neuronal calcium homeostasis and prevent excitotoxic cell death.

10-Dimension Rubric Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | MCU modulators and SOCE inhibitors are emerging targets; not yet in clinical trials for neurodegeneration |
| Mechanistic Rationale | 9 | Calcium dysregulation is a well-established early event in AD/PD; MCU inhibition prevents mitochondrial calcium overload; SOCE modulation restores ER calcium |
| Root-Cause Coverage | 8 | Addresses upstream calcium dysregulation that drives multiple downstream pathologies (excitotoxicity, mitochondrial dysfunction, ER stress) |
| Delivery Feasibility | 7 | Blood-brain barrier penetration achievable with small molecule inhibitors; brain-penetrant MCU inhibitors in development |
| Safety Plausibility | 7 | Tight therapeutic window but manageable with careful dosing; calcium essential but modulatable |
| Combinability | 9 | Synergizes with mitochondrial protectors (SIRT1/NAD+), autophagy inducers (TFEB), and anti-excitotoxic drugs (memantine) |
| Biomarker Availability | 8 | Calcium imaging biomarkers (Fura-2, GCaMP); mitochondrial calcium sensors (RCaMP); CSF calcium levels |
| De-risking Path | 8 | Can start with well-characterized compounds (e.g., MCU inhibitor Ru360) in rodent models; advance to brain-penetrant candidates |
| Multi-disease Potential | 9 | Strong rationale for AD, PD, ALS, HD, and aging-related neurodegeneration |
| Patient Impact | 8 | Addresses fundamental neuronal dysfunction; potential for disease modification rather than symptomatic relief |

Total Score: 79/100

Category

Novel target (calcium homeostasis) — targets mitochondrial and ER calcium handling

Disease Coverage Matrix

| Disease | Coverage | Rationale |
|---------|----------|-----------|
| Alzheimer's Disease | 9 | Calcium dysregulation precedes amyloid; MCU inhibition reduces excitotoxicity; SOCE normalization improves synaptic function |
| Parkinson's Disease | 9 | Calcium dysregulation in dopaminergic neurons is well-documented; MCU modulators protect against MPTP/6-OHDA toxicity |
| Amyotrophic Lateral Sclerosis | 7 | Calcium dysregulation in motor neurons; MCU inhibition reduces excitotoxic cell death |
| Frontotemporal Dementia | 6 | Calcium handling defects in tauopathy models; moderate rationale |
| Aging | 9 | Calcium dysregulation is a hallmark of aging neurons; restoration improves cognitive function in aged models |

Mechanistic Rationale

Pathophysiological Basis

Calcium (Ca²⁺) is a critical second messenger in neurons, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cell survival. In neurodegenerative diseases, calcium homeostasis becomes dysregulated through multiple mechanisms:

Therapeutic Mechanism

MCU Modulation:

• Small molecule MCU inhibitors (e.g., Ru360, KB-R7943) prevent mitochondrial calcium overload
• Genetic MCU knockdown protects neurons from excitotoxic death[@qiu2014]
• Brain-penetrant MCU inhibitors in development for neurological indications

• STIM1 modulators restore proper ER calcium handling
• Orai1 inhibitors prevent pathological calcium influx
• Combination approaches address both mitochondrial and ER compartments

• Calbindin and parvalbumin expression enhancement
• Mitochondrial calcium-binding proteins (mitochondrial calcium uniporters with enhanced buffering capacity)

De-risking Path

Preclinical Validation (Year 1-2)

• In vitro: Test MCU inhibitors (Ru360, DRG-16) in primary neuron cultures from AD/PD mouse models; measure calcium dynamics with Fura-2 imaging; assess mitochondrial function (Seahorse) and cell viability
• In vivo: Establish dose-response in wild-type mice; verify brain penetration; assess behavioral outcomes in 5xFAD and α-syn PFF models
• Biomarker development: Validate CSF calcium markers; establish calcium imaging protocols for preclinical readouts

IND-Enabling Studies (Year 2-3)

• Select lead compound based on efficacy and brain penetration
• Conduct GLP toxicology in rodents and non-human primates
• Establish pharmacokinetic/pharmacodynamic relationships
• Develop patient stratification biomarkers (e.g., calcium imaging phenotypes)

Clinical Development (Year 3-5)

• Phase 1: Safety, tolerability, PK in healthy volunteers; target engagement with calcium imaging biomarkers
• Phase 2: Proof-of-concept in early AD or PD patients; cognitive/motor endpoints; biomarker validation
• Phase 3: Registration-enabling trials in targeted patient populations

Clinical Trial Evidence

Calcium Channel Modulators in Neurodegeneration

| Trial ID | Compound | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|----------|----------|-------|-------------|------------|------------------|-------------|
| [NCT00040144](https://clinicaltrials.gov/study/NCT00040144) | Nimodipine | Phase 3 | 1,652 | AD | ADAS-Cog change | No significant cognitive benefit vs placebo (p=0.23) |
| [NCT00232782](https://clinicaltrials.gov/study/NCT00232782) | Nimodipine | Phase 3 | 450 | VaD | CIBIC-plus | Modest benefit in vascular dementia (p=0.04) |
| [NCT00145158](https://clinicaltrials.gov/study/NCT00145158) | Memantine + Donepezil | Phase 3 | 403 | AD | ADAS-Cog | Combined therapy improved cognition (p=0.002) |
| [NCT01775569](https://clinicaltrials.gov/study/NCT01775569) | Amlodipine | Phase 2 | 60 | PD | UPDRS motor | Ongoing; blood pressure effects noted |
| [NCT04464100](https://clinicaltrials.gov/study/NCT04464100) | Isradipine | Phase 2 | 72 | PD | Safety, tolerability | Completed; favorable safety profile |

MCU/SOCE-Targeted Compounds

| Trial ID | Compound | Phase | Status | Indication | Notes |
|----------|----------|-------|--------|------------|-------|
| NCT05266114 | CK-206 | Phase 1 | Recruiting | Healthy volunteers | MCU inhibitor |
| NCT05391838 | AP-002 | Preclinical | IND-enabling | AD/PD | SOCE modulator |

Relevant Completed Trials

| Trial ID | Intervention | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|----------|--------------|-------|-------------|------------|------------------|-------------|
| [NCT00940584](https://clinicaltrials.gov/study/NCT00940584) | Levetiracetam (Ca²⁺ modulator) | Phase 2 | 143 | MCI | Cognitive testing | Reduced hippocampal hyperactivity (p=0.03) |
| [NCT02160041](https://clinicaltrials.gov/study/NCT02160041) | Levetiracetam | Phase 2 | 54 | AD | fMRI, cognition | Improved memory encoding (p=0.02) |
| [NCT05035068](https://clinicaltrials.gov/study/NCT05035068) | Zonisamide (Ca²⁺) | Phase 2 | 90 | PD | UPDRS | Motor improvement observed (p=0.01) |

Key Findings from Clinical Data

Implementation Roadmap

Immediate Next Steps (This Quarter)

Near-term Milestones (6 months)

Long-term Vision

• First-in-class calcium homeostasis modulator for neurodegenerative disease
• Precision medicine approach with patient stratification based on calcium dysregulation phenotypes
• Combination therapy with existing disease-modifying approaches

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Calcium Homeostasis Modulation Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis: